Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Managing thyroid cancer without thyroxine withdrawal.

Pedro Weslley S do Rosário1, Flavio P J Vasconcelos, Ludmilla D Cardoso

  • 1Department of Thyroid, Santa Casa de Belo Horizonte, MG. pedrorosario@globo.com

Arquivos Brasileiros De Endocrinologia E Metabologia
|April 22, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study.

Endocrine connections·2019
Same author

Diabetes and other endocrine-metabolic abnormalities in the long-term follow-up of pancreas transplantation.

Clinical diabetes and endocrinology·2017
Same author

Seventy two-hour glucose monitoring profiles in mild gestational diabetes mellitus: differences from healthy pregnancies and influence of diet counseling.

European journal of endocrinology·2016
Same author

IMAGES IN CLINICAL MEDICINE. Acanthosis Nigricans and Insulin Resistance.

The New England journal of medicine·2016
Same author

Glucose control in pancreas transplantation assessed by 72-hr continuous glucose monitoring.

Transplantation·2012
Same author

Biochemical acromegaly in patients with prolactinoma during treatment with dopaminergic agonists.

Arquivos brasileiros de endocrinologia e metabologia·2010
Same journal

PTPN2 gene polymorphisms are associated with type 1 diabetes mellitus in Brazilian subjects?

Arquivos brasileiros de endocrinologia e metabologia·2015
Same journal

PTPN2, a potential therapeutic target for type 1 diabetes?

Arquivos brasileiros de endocrinologia e metabologia·2015
Same journal

Response to the letter: Red cell distribution width in subclinical hypothyroidism.

Arquivos brasileiros de endocrinologia e metabologia·2015
Same journal

Red cell distribution width in subclinical hypothyroidism.

Arquivos brasileiros de endocrinologia e metabologia·2015
Same journal

Response to the letter: Angiotensin-II induced insulin resistance.

Arquivos brasileiros de endocrinologia e metabologia·2015
Same journal

Angiotensin-II induced insulin resistance.

Arquivos brasileiros de endocrinologia e metabologia·2015
See all related articles

Thyroid cancer patients can prepare for treatment using a reduced thyroxine (T4) dose, avoiding severe hypothyroidism. This method effectively stimulates thyroglobulin (Tg) for scanning and therapy, offering an alternative to T4 withdrawal or recombinant TSH.

Area of Science:

  • Endocrinology
  • Oncology
  • Nuclear Medicine

Background:

  • Thyroid cancer management often requires stimulating thyroglobulin (Tg) levels for diagnostic imaging and radioactive iodine therapy.
  • Traditional preparation methods include thyroxine (T4) withdrawal or recombinant thyroid-stimulating hormone (TSH), which can cause significant hypothyroidism symptoms.

Purpose of the Study:

  • To evaluate a T4 dose reduction protocol as a less burdensome alternative for preparing thyroid cancer patients for whole-body scanning (WBS) and iodine-131 treatment.
  • To compare the efficacy and patient experience of T4 dose reduction versus T4 withdrawal.

Main Methods:

  • Fifty-one patients with thyroid carcinoma underwent preparation using either total T4 withdrawal or a T4 dose reduction protocol (0.8 microg/kg/day).
  • Thyroid-stimulating hormone (TSH) levels were monitored weekly, with Tg assays performed when TSH exceeded 30 mIU/l.

Related Experiment Videos

  • Clinical and laboratory parameters, including hypothyroidism symptoms, creatine kinase (CK), and LDL cholesterol, were assessed for both groups.

    • Main Results:

    • The T4 dose reduction protocol successfully achieved TSH levels > 30 mIU/l in 84.6% of patients within 6 weeks and 100% within 8 weeks.
    • Patients undergoing T4 withdrawal experienced more frequent symptoms of hypothyroidism, elevated CK, and increased LDL cholesterol.
    • The T4 dose reduction protocol was effective for Tg stimulation and subsequent ablative therapy.

    Conclusions:

    • A T4 dose reduction protocol is a viable and effective strategy for preparing thyroid cancer patients for WBS and iodine-131 treatment.
    • This protocol mitigates the severe hypothyroidism and associated laboratory abnormalities seen with T4 withdrawal.
    • The T4 dose reduction method offers a more tolerable and potentially cost-effective alternative to recombinant TSH.